1
|
Fang H, Li J, Zhang L, Li B, Song J, Lu X, Niu Q, Wang L. LncRNA 51A: A promising diagnostic biomarker for assessing cognitive decline in occupationally exposed aluminum workers. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2024; 111:104548. [PMID: 39222898 DOI: 10.1016/j.etap.2024.104548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2024] [Revised: 08/03/2024] [Accepted: 08/25/2024] [Indexed: 09/04/2024]
Abstract
OBJECTIVE To assess the diagnostic utility of lncRNA 51 A in detecting cognitive decline among aluminum-exposed workers occupationally. METHODS 921 male workers from an aluminum manufacturing facility underwent cognitive assessments, measurement of plasma aluminum levels and quantification of lncRNA 51 A levels. Receiver Operating Characteristic (ROC) curves were constructed to assess the diagnostic potential of lncRNA 51 A. Bayesian network model was utilized to predict the likelihood of cognitive decline among the study population. RESULTS Significant differences in lncRNA 51 A levels, plasma aluminum concentration and MMSE scores were observed between cognitive normal and decline groups. The lncRNA 51 A expression was negatively correlated with MMSE scores. The area under the curve (AUC) was 0.894, with 89.3 % sensitivity and 73.9 % specificity. The Bayesian network model indicated varying probabilities of cognitive decline based on lncRNA 51 A expression levels. CONCLUSION Plasma lncRNA 51 A shows potential as an excellent biomarker for cognitive decline diagnosis in aluminum-exposed workers.
Collapse
Affiliation(s)
- Hailun Fang
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China
| | - Juan Li
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China
| | - Lei Zhang
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China
| | - Baichun Li
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China
| | - Jing Song
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China; Shanxi Key Laboratory of Environmental Health Impairment and Prevention, Shanxi Medical University, Taiyuan, China; NHC Key Laboratory of Pneumoconiosis, Shanxi Medical University, Taiyuan, China; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention,Shanxi Medical University, Taiyuan, China
| | - Xiaoting Lu
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China; Shanxi Key Laboratory of Environmental Health Impairment and Prevention, Shanxi Medical University, Taiyuan, China; NHC Key Laboratory of Pneumoconiosis, Shanxi Medical University, Taiyuan, China; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention,Shanxi Medical University, Taiyuan, China
| | - Qiao Niu
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China; Shanxi Key Laboratory of Environmental Health Impairment and Prevention, Shanxi Medical University, Taiyuan, China; NHC Key Laboratory of Pneumoconiosis, Shanxi Medical University, Taiyuan, China; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention,Shanxi Medical University, Taiyuan, China
| | - Linping Wang
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China; Shanxi Key Laboratory of Environmental Health Impairment and Prevention, Shanxi Medical University, Taiyuan, China; NHC Key Laboratory of Pneumoconiosis, Shanxi Medical University, Taiyuan, China; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention,Shanxi Medical University, Taiyuan, China.
| |
Collapse
|
2
|
Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 2023; 37:5-17. [PMID: 36309558 DOI: 10.1038/s41375-022-01736-5] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 10/11/2022] [Accepted: 10/14/2022] [Indexed: 02/01/2023]
Abstract
The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has been a model for cancer therapy development. Though most patients with CML have a normal quality and duration of life with TKI therapy, some patients progress to accelerated phase (AP) and blast phase (BP), both of which have a relatively poor prognosis. The rates of progression have reduced significantly from over >20% in the pre-TKI era to <5% now, largely due to refinements in CML therapy and response monitoring. Significant insights have been gained into the mechanisms of disease transformation including the role of additional cytogenetic abnormalities, somatic mutations, and other genomic alterations present at diagnosis or evolving on therapy. This knowledge is helping to optimize TKI therapy, improve prognostication and inform the development of novel combination regimens in these patients. While patients with de novo CML-AP have outcomes almost similar to CML in chronic phase (CP), those transformed from previously treated CML-CP should receive second- or third- generation TKIs and be strongly considered for allogeneic stem cell transplantation (allo-SCT). Similarly, patients with transformed CML-BP have particularly dismal outcomes with a median survival usually less than one year. Combination regimens with a potent TKI such as ponatinib followed by allo-SCT can achieve long-term survival in some transformed BP patients. Regimens including venetoclax in myeloid BP or inotuzumab ozogamicin or blinatumomab in lymphoid BP might lead to deeper and longer responses, facilitating potentially curative allo-SCT for patients with CML-BP once CP is achieved. Newer agents and novel combination therapies are further expanding the therapeutic arsenal in advanced phase CML.
Collapse
Affiliation(s)
- Jayastu Senapati
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Elias Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Hagop Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nicholas J Short
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
3
|
Quan D, Ren J, Ren H, Linghu L, Wang X, Li M, Qiao Y, Ren Z, Qiu L. Exploring influencing factors of chronic obstructive pulmonary disease based on elastic net and Bayesian network. Sci Rep 2022; 12:7563. [PMID: 35534641 PMCID: PMC9085890 DOI: 10.1038/s41598-022-11125-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Accepted: 04/08/2022] [Indexed: 01/15/2023] Open
Abstract
AbstractThis study aimed to construct Bayesian networks (BNs) to analyze the network relationships between COPD and its influencing factors, and the strength of each factor's influence on COPD was reflected through network reasoning. Elastic Net and Max-Min Hill-Climbing (MMHC) algorithm were adopted to screen the variables on the surveillance data of COPD among residents in Shanxi Province, China from 2014 to 2015, and construct BNs respectively. 10 variables finally entered the model after screening by Elastic Net. The BNs constructed by MMHC showed that smoking status, household air pollution, family history, cough, air hunger or dyspnea were directly related to COPD, and Gender was indirectly linked to COPD through smoking status. Moreover, smoking status, household air pollution and family history were the parent nodes of COPD, and cough, air hunger or dyspnea represented the child nodes of COPD. In other words, smoking status, household air pollution and family history were related to the occurrence of COPD, and COPD would make patients’ cough, air hunger or dyspnea worse. Generally speaking, BNs could reveal the complex network linkages between COPD and its relevant factors well, making it more convenient to carry out targeted prevention and control of COPD.
Collapse
|
4
|
Leclerc V, Ducher M, Ceraulo A, Bertrand Y, Bleyzac N. A Clinical Decision Support Tool to Find the Best Initial Intravenous Cyclosporine Regimen in Pediatric Hematopoietic Stem Cell Transplantation. J Clin Pharmacol 2021; 61:1485-1492. [PMID: 34105165 DOI: 10.1002/jcph.1924] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Accepted: 06/04/2021] [Indexed: 12/20/2022]
Abstract
To optimize cyclosporine A (CsA) dosing regimen in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT), we aimed to provide clinicians with a validated decision support tool for determining the most suitable first dose of intravenous CsA. We used a 10-year monocentric data set of pediatric patients undergoing HSCT. Discretization of all variables was performed according to literature or thanks to algorithms using Shannon entropy (from information theory) or equal width intervals. The first 8 years were used to build the Bayesian network model. This model underwent a 10-fold cross-validation, and then a prospective validation with data of the last 2 years. There were 3.3% and 4.1% of missing values in the training and the validation data set, respectively. After prospective validation, the Tree-Augmented Naïve Bayesian network shows interesting prediction performances with an average area under the receiver operating characteristic curve of 0.804, 32.8% of misclassified patients, a true-positive rate of 0.672, and a false-positive rate of 0.285. This validated model allows good predictions to propose an optimized and personalized initial CsA dose for pediatric patients undergoing HSCT. The clinical impact of its use should be further evaluated.
Collapse
Affiliation(s)
- Vincent Leclerc
- Targeted Therapies in Oncology, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France.,Pharmacy Department, Hôpital Pierre Garraud, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France
| | - Michel Ducher
- Targeted Therapies in Oncology, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France.,Pharmacy Department, Hôpital Pierre Garraud, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France
| | - Antony Ceraulo
- Institute of Pediatric Hematology and Oncology (IHOPe), Hematology Unit, Hospices Civils de Lyon and Claude Bernard University, Lyon, France
| | - Yves Bertrand
- Institute of Pediatric Hematology and Oncology (IHOPe), Hematology Unit, Hospices Civils de Lyon and Claude Bernard University, Lyon, France
| | - Nathalie Bleyzac
- Targeted Therapies in Oncology, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France
| |
Collapse
|
5
|
Zhu C, Wu J, Liu M, Wang L, Li D, Kouvelas A. Recovery preparedness of global air transport influenced by COVID-19 pandemic: Policy intervention analysis. TRANSPORT POLICY 2021; 106:54-63. [PMID: 33785994 PMCID: PMC7995335 DOI: 10.1016/j.tranpol.2021.03.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 03/10/2021] [Indexed: 05/21/2023]
Abstract
The outbreak of COVID-19 constitutes an unprecedented disruption globally, in which risk management framework is on top priority in many countries. Travel restriction and home/office quarantine are some frequently utilized non-pharmaceutical interventions, which bring the worst crisis of airline industry compared with other transport modes. Therefore, the post-recovery of global air transport is extremely important, which is full of uncertainty but rare to be studied. The explicit/implicit interacted factors generate difficulties in drawing insights into the complicated relationship and policy intervention assessment. In this paper, a Causal Bayesian Network (CBN) is utilized for the modelling of the post-recovery behaviour, in which parameters are synthesized from expert knowledge, open-source information and interviews from travellers. The tendency of public policy in reaction to COVID-19 is analyzed, whilst sensitivity analysis and forward/backward belief propagation analysis are conducted. Results show the feasibility and scalability of this model. On condition that no effective health intervention method (vaccine, medicine) will be available soon, it is predicted that nearly 120 days from May 22, 2020, would be spent for the number of commercial flights to recover back to 58.52%-60.39% on different interventions. This intervention analysis framework is of high potential in the decision making of recovery preparedness and risk management for building the new normal of global air transport.
Collapse
Affiliation(s)
- Chunli Zhu
- Department of Civil Engineering, Tsinghua University, Beijing, 100084, PR China
- Institute for Transport Planning and Systems, ETH Zürich, Zürich, 8093, Switzerland
| | - Jianping Wu
- Department of Civil Engineering, Tsinghua University, Beijing, 100084, PR China
| | - Mingyu Liu
- Department of Civil Engineering, Tsinghua University, Beijing, 100084, PR China
| | - Linyang Wang
- Department of Civil Engineering, Tsinghua University, Beijing, 100084, PR China
| | - Duowei Li
- Department of Civil Engineering, Tsinghua University, Beijing, 100084, PR China
| | - Anastasios Kouvelas
- Institute for Transport Planning and Systems, ETH Zürich, Zürich, 8093, Switzerland
| |
Collapse
|
6
|
Hassaine A, Salimi-Khorshidi G, Canoy D, Rahimi K. Untangling the complexity of multimorbidity with machine learning. Mech Ageing Dev 2020; 190:111325. [PMID: 32768443 PMCID: PMC7493712 DOI: 10.1016/j.mad.2020.111325] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/28/2020] [Accepted: 07/30/2020] [Indexed: 12/20/2022]
Abstract
The prevalence of multimorbidity has been increasing in recent years, posing a major burden for health care delivery and service. Understanding its determinants and impact is proving to be a challenge yet it offers new opportunities for research to go beyond the study of diseases in isolation. In this paper, we review how the field of machine learning provides many tools for addressing research challenges in multimorbidity. We highlight recent advances in promising methods such as matrix factorisation, deep learning, and topological data analysis and how these can take multimorbidity research beyond cross-sectional, expert-driven or confirmatory approaches to gain a better understanding of evolving patterns of multimorbidity. We discuss the challenges and opportunities of machine learning to identify likely causal links between previously poorly understood disease associations while giving an estimate of the uncertainty on such associations. We finally summarise some of the challenges for wider clinical adoption of machine learning research tools and propose some solutions.
Collapse
Affiliation(s)
- Abdelaali Hassaine
- Deep Medicine, Oxford Martin School, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom
| | - Gholamreza Salimi-Khorshidi
- Deep Medicine, Oxford Martin School, University of Oxford, Oxford, United Kingdom; Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom
| | - Dexter Canoy
- Deep Medicine, Oxford Martin School, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom
| | - Kazem Rahimi
- Deep Medicine, Oxford Martin School, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom.
| |
Collapse
|
7
|
Khayi F, Lafarge L, Terret C, Albrand G, Falquet B, Culine S, Gourgou S, Ducher M, Bourguignon L. Prediction of docetaxel toxicity in older cancer patients: a Bayesian network approach. Fundam Clin Pharmacol 2019; 33:679-686. [DOI: 10.1111/fcp.12476] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 03/28/2019] [Accepted: 04/25/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Fouzy Khayi
- Hospices Civils de Lyon Hôpital Pierre Garraud 136 rue du commandant Charcot 69005 Lyon France
| | - Laurent Lafarge
- Hospices Civils de Lyon Hôpital Pierre Garraud 136 rue du commandant Charcot 69005 Lyon France
| | - Catherine Terret
- Department of Medical Oncology Centre Léon Bérard 28 Prom. Léa et Napoléon Bullukian 69008 Lyon France
| | - Gilles Albrand
- Hospices Civils de Lyon Centre Hospitalier Lyon Sud 165 Chemin du Grand Revoyet 69310 Pierre‐Bénite France
| | - Benoit Falquet
- Hospices Civils de Lyon Hôpital Pierre Garraud 136 rue du commandant Charcot 69005 Lyon France
| | - Stéphane Culine
- Department of Medical Oncology AP‐HP Hôpital Saint‐Louis 1 Avenue Claude Vellefaux 75010 Paris France
- Paris‐Diderot University Paris France
| | - Sophie Gourgou
- Institut du cancer de Montpellier unité de biométrie, 208, avenue des Apothicaires 34298 Montpellier France
- Université de Montpellier 163, rue Auguste‐Broussonnet 34090 Montpellier France
| | - Michel Ducher
- Hospices Civils de Lyon Hôpital Pierre Garraud 136 rue du commandant Charcot 69005 Lyon France
- EMR 3738 Faculté de médecine Lyon‐sud Université Lyon 1 69310 Pierre‐Bénite Lyon France
| | - Laurent Bourguignon
- Hospices Civils de Lyon Hôpital Pierre Garraud 136 rue du commandant Charcot 69005 Lyon France
- UMR CNRS 5558 Laboratoire de Biométrie et Biologie Évolutive Université Lyon 1 69100 Villeurbanne Lyon France
- ISPB – Faculté de pharmacie Université Lyon 1 8 Avenue Rockefeller 69008 Lyon France
| |
Collapse
|
8
|
Melge AR, Kumar LG, K P, Nair SV, K M, C GM. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations. J Biomol Struct Dyn 2019; 37:4747-4766. [DOI: 10.1080/07391102.2018.1559765] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Anu R. Melge
- Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi Campus, Kerala State, India
| | - Lekshmi G. Kumar
- Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi Campus, Kerala State, India
| | - Pavithran K
- Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi Campus, Kerala State, India
| | - Shantikumar V. Nair
- Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi Campus, Kerala State, India
| | - Manzoor K
- Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi Campus, Kerala State, India
| | - Gopi Mohan C
- Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi Campus, Kerala State, India
| |
Collapse
|